DMII DRUGS MADE IN AMER ACQ II CO revenue, earnings and financials
For the quarter ended June 30, 2026, DRUGS MADE IN AMER ACQ II CO reported revenue of n/a, net income of $4.40M and diluted EPS of n/a; for the fiscal year ended December 2025 revenue was n/a.
DMII annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$488K, net income $4.19M (margin n/a), EPS n/a
DMII quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income $4.40M, EPS n/a
- Quarter ended Mar 31, 2026: revenue n/a, net income $4.34M, EPS n/a
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income $4.33M, EPS n/a
- Quarter ended Sep 30, 2025: revenue n/a, net income −$46.2K, EPS n/a
- Quarter ended Jun 30, 2025: revenue n/a, net income −$38.1K, EPS n/a
- Quarter ended Mar 31, 2025: revenue n/a, net income −$59.3K, EPS n/a
- Quarter ended Dec 31, 2024: revenue n/a, net income −$152K, EPS n/a
DMII cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$1.02M, share buybacks n/a
DMII balance sheet
- Jun 30, 2026: cash $175K, total assets $514M, total liabilities $18.1M, shareholders' equity −$17.9M
- Mar 31, 2026: cash $348K, total assets $510M, total liabilities $18.2M, shareholders' equity −$17.8M
- Dec 31, 2025: cash $223, total assets $505M, total liabilities $17.8M, shareholders' equity −$17.8M
- Sep 30, 2025: cash n/a, total assets $501M, total liabilities $18.2M, shareholders' equity −$17.3M
- Dec 31, 2024: cash n/a, total assets $138K, total liabilities $255K, shareholders' equity −$117K
Is DMII profitable?
Yes. DRUGS MADE IN AMER ACQ II CO earned $13.0M over the last four quarters.